摘要
目的探究利司那肽治疗老年2型糖尿病轻度认知功能障碍的效果及安全性。方法选取江苏省淮安市肿瘤医院2019年4月至2021年4月接诊的82例老年2型糖尿病轻度认知障碍患者,根据治疗方案将其分为试验组和对照组,对照组(41例)予以胰岛素注射治疗,试验组(41例)在对照组的基础上联合利司那肽治疗。比较两组治疗12周后的血糖、认知功能、神经功能指标,记录两组不良反应发生情况。结果两组治疗后糖化血红蛋白、早餐前空腹血糖、餐后2 h血糖水平均低于治疗前,且试验组低于对照组(P<0.05)。治疗后,两组蒙特利尔认知评估量表评分均高于治疗前,美国国立卫生院卒中量表评分均低于治疗前,且试验组蒙特利尔认知评估量表评分高于对照组,美国国立卫生院卒中量表评分低于对照组(P<0.05)。治疗后,两组血清中枢神经特异性蛋白(S100β)、血浆β-淀粉样蛋白-42水平均低于治疗前,且试验组低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论利司那肽应用于老年2型糖尿病轻度认知功能障碍患者治疗中,有助于降低血糖水平,改善认知功能且安全性良好。
Objective To explore the efficacy and safety of Risenatide in the treatment of mild cognitive impairment in elderly patients with type 2 diabetes mellitus.Methods A total of 82 elderly patients with type 2 diabetes mellitus and mild cognitive impairment admitted to Huaian Cancer Hospital,Jiangsu Province from April 2019 to April 2021 were selected and divided into experimental group and control group according to the treatment plan.The control group(41 cases)was treated with insulin injection,and the experimental group(41 cases)was treated with Risenatide on the basis of the control group.The blood glucose,cognitive function,and neurological function index were compared between the two groups after 12 weeks of treatment,and the incidence of adverse reactions was recorded.Results The levels of glycosylated hemoglobin,fasting blood glucose before breakfast,and 2 h postprandial blood glucose in the two groups after treatment were lower than those before treatment,and those in the experimental group were lower than those in the control group(P<0.05).After treatment,the scores of Montreal cognitive assessment scale in the two groups were higher than those before treatment,the scores of National Institutes of Health stroke scale in the two groups were lower than those before treatment,and the scores of Montreal cognitive assessment scale in the experimental group were higher than those in the control group,and the scores of National Institutes of Health stroke scale were lower than those in the control group(P<0.05).After treatment,the levels of serum central nervous specific protein(S100β)and plasmaβ-amyloid protein-42 in the two groups were lower than those before treatment,and the experimental group was lower than the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of Risenatide in the treatment of mild cognitive impairment in elderly patients with type 2 diabetes mellitus can contribute to lower blood g
作者
朱平
吴新华
马立明
严妍
时雯
余涛
黄玉杰
周洁
ZHU Ping;WU Xinhua;MA Liming;YAN Yan;SHI Wen;YU Tao;HUANG Yujie;ZHOU Jie(Department of Endocrinology,Huaian Cancer Hospital,Jiangsu Province,Huaian223000,China)
出处
《中国医药导报》
CAS
2022年第30期79-82,共4页
China Medical Herald
基金
江苏省卫生健康委员会项目(LKM2022071)
江苏省淮安市科技项目(HAB202050)
江苏省医院协会医院管理创新研究项目(JSYGY-3-2018-195)。
关键词
老年
2型糖尿病
认知功能障碍
利司那肽
Elderly
Type 2 diabetes mellitus
Cognitive dysfunction
Risenatide
